KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial. PMID 40890873 · Cardiooncology · 2025-Sep-01 The record describes the rationale and design of a randomized clinical trial but explicitly states it is ongoing with no results. It is a protocol report. Furthermore, the primary endpoint is cardiotoxicity incidence, which is not a time-to-event oncology efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial. PMID 40890782 · Trials · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Optimizing short-term antibiotic treatment in patients with acute cholangitis: study protocol for an open-label randomized controlled trial (the BOLT-P3 trial). PMID 40890775 · Trials · 2025-Sep-01 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of a self-made dietary therapy formula on the improvement of enteral feeding intolerance in patients with laryngeal cancer after surgery: A randomized controlled trial. PMID 40888947 · Support Care Cancer · 2025-Sep-01 The study is an oncology RCT with original results, but it is excluded because: (1) it does not have a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.)—the primary outcomes are complications and nutritional parameters; (2) the intervention is a non-drug dietary formula, not a drug; (3) the trial phase is not specified, and there is no signal for Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer. PMID 40888443 · Endocr Relat Cancer · 2025-Sep-01 Study is an eligible Phase III randomized drug trial in oncology, but its primary endpoints are pathological response scores (PEPI, EPclin), not a pre-specified time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Managing, not lessening, uncertainty: a novel mind-body intervention for fear of cancer recurrence. PMID 40887510 · J Cancer Surviv · 2025-Sep-01 Excluded: Not a Phase III/IIIb or Phase II/III randomized trial; no drug intervention; primary/key endpoint is not time-to-event; intervention is non-drug psycho-oncology; report is secondary analysis of pilot study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis. PMID 40773752 · J Basic Clin Physiol Pharmacol · 2025-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. PMID 40742738 · JAMA Oncol · 2025-Sep-01 The study is an oncology RCT with a drug intervention and original results, but it does not meet all required criteria: it is not a definitive Phase III trial, and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS) but a continuous measure of agitation severity.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. PMID 40694530 · Diabetes Care · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial. PMID 40658410 · JAMA Neurol · 2025-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial. PMID 40638104 · JAMA Oncol · 2025-Sep-01 The record meets most eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result). However, it fails the explicit requirement for a Phase III/IIIb or Phase II/III trial, as the phase is not clearly stated in the provided metadata. Therefore, is_eligible is set to false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial. PMID 40621831 · J Hypertens · 2025-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials. PMID 40600894 · J Natl Cancer Inst · 2025-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. PMID 40560559 · JAMA Dermatol · 2025-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. PMID 40560554 · JAMA Dermatol · 2025-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. PMID 40543068 · Diabetes Care · 2025-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of tourniquet application on postoperative delirium in elderly patients undergoing total knee arthroplasty: a randomized clinical trial. PMID 40540295 · Int J Surg · 2025-Sep-01 This is a randomized clinical trial in humans, but it is not an oncology study (tourniquet use in total knee arthroplasty), lacks a time-to-event efficacy endpoint (primary outcome is incidence of delirium, not OS/PFS/etc.), and has no drug intervention (surgical/anesthesia-related). It does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults. PMID 40515653 · J Natl Cancer Inst · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Carcinogen reduction in a randomized controlled study comparing e-cigarette provision to assessment only among people with serious mental illness who smoke. PMID 40505215 · Drug Alcohol Depend · 2025-Sep-01 The study is a randomized trial in humans with original results, but it is not an oncology trial (focus is harm reduction via e-cigarette provision to reduce carcinogen exposure, not treatment of a human malignant neoplasm). It does not involve a drug-containing intervention (e-cigarette provision is a device, not a drug). It does not report a time-to-event efficacy endpoint (primary outcome is biomarker change in NNAL, not OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Optimal Head-of-Bed Positioning Before Thrombectomy in Large Vessel Occlusion Stroke: A Randomized Clinical Trial. PMID 40465238 · JAMA Neurol · 2025-Sep-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
NOVEMBER, A Phase 2 Trial of a 9-Day Course of Whole Breast Radiation Therapy With a Simultaneous Lumpectomy Boost for Early-Stage Breast Cancer. PMID 40314623 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial. PMID 40312101 · J Rheumatol · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies. PMID 40233987 · J Rheumatol · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hypofractionated Versus Single-Session Radiosurgery to Preserve Hearing in Patients Affected by Sporadic Vestibular Schwannoma: The ACOUNEU Randomized Clinical Trial. PMID 40222395 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The study is a randomized clinical trial in oncology with a time-to-event primary endpoint (hearing preservation hazard ratio) and reports primary results. However, it is not eligible because the intervention is not drug-containing (it compares two radiotherapy fractionation schedules, not a drug). Additionally, the trial phase is not explicitly confirmed as Phase III or a definitive trial in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months. PMID 40187573 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The trial is randomized, human, oncologic, and reports time-to-event efficacy endpoints. However, it is ineligible because the intervention is not a drug-containing one; it compares two radiation therapy modalities (HDR vs. LDR brachytherapy). Additionally, the phase of the trial is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study. PMID 40185210 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group. PMID 40185209 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The record describes a Phase III randomized trial in pediatric oncology (rhabdomyosarcoma) but evaluates radiotherapy dose escalation and modalities (proton vs. photon), not a drug-containing intervention. The reported endpoints are local failure rates (percentages), not time-to-event endpoints like OS, PFS, DFS, or Kaplan-Meier analyses. Therefore, it does not meet the drug intervention or time-to-event efficacy criteria.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. PMID 40184206 · Inflamm Bowel Dis · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Preventing pulmonary complications after laparoscopic colorectal surgery: a lung-protective protocol vs. standard care: A randomised controlled trial. PMID 40159954 · Eur J Anaesthesiol · 2025-Sep-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. PMID 40109195 · Haematologica · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial. PMID 40079105 · Haematologica · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial. PMID 41647992 · ESMO Gastrointest Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study. PMID 41647991 · ESMO Gastrointest Oncol · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ascorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial. PMID 41574117 · CHEST Crit Care · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Development, usability, and randomized pilot feasibility study of a mobile application prototype supporting self-management of accidental bowel leakage. PMID 41311646 · Continence (Amst) · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of Immunotherapy in Treating Metastatic Melanoma: A Randomized Controlled Trial. PMID 41164606 · J Pharm Bioallied Sci · 2025-Sep The record describes a randomized trial in oncology with a drug intervention and primary time-to-event endpoints (PFS, OS). However, the abstract does not explicitly state the trial phase (e.g., Phase III, Phase II/III). Per adjudication rules, phase cannot be inferred. Therefore, the 'phase3_or_definitive' criterion cannot be established, making the record ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2). PMID 41158898 · Cureus · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Conventional partial pancreatoduodenectomy versus an uncinate first, extended partial pancreatoduodenectomy approach for the resection of pancreatic head cancer: the randomized, controlled PancER trial. PMID 41143201 · Innov Surg Sci · 2025-Sep 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
FDA-Approved HIV-1 Capsid Inhibition With Lenacapavir: A Paradigm Shift in Pre-exposure Prophylaxis. PMID 41084700 · Cureus · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib. PMID 41071292 · Ann Hematol · 2025-Sep The report is from a Phase III oncology RCT with drug intervention, but the specific analysis presented is a secondary analysis of quality-of-life data, not a report of a primary or key secondary time-to-event efficacy endpoint. Therefore, it does not meet the inclusion criteria for a primary result report of a time-to-event endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial. PMID 41054436 · EClinicalMedicine · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial. PMID 41025990 · Radiology · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Colorectal Cancer and Advanced Adenoma after Single CT Colonography or Biennial FIT Screening in the SAVE Randomized Controlled Trial. PMID 41025989 · Radiology · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study. PMID 41018703 · Open Forum Infect Dis · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). PMID 41002192 · Cephalalgia · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Photodynamic Therapy for Peripheral Lung Cancer]. PMID 40998354 · Kyobu Geka · 2025-Sep The study is a randomized, multicenter trial in human oncology (NSCLC) with a primary time-to-event endpoint (PFS) and Kaplan-Meier analysis, making it potentially eligible. However, the intervention is Photodynamic Therapy (PDT), which is a device/light-based treatment, not a drug-containing intervention. The explicit phase is not stated in the metadata, and cannot be inferred from the drug name (as per instructions). Therefore, it does not meet the 'drug intervention' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. PMID 40990131 · Alzheimers Dement · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PMID 40972137 · PLoS Med · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines. PMID 40968493 · J Cosmet Dermatol · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda. PMID 40966190 · PLoS Med · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -